CF
SNDX icon

Corebridge Financial’s Syndax Pharmaceuticals SNDX Stock Holding History

Corebridge Financial’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-40,255
Closed -$495K – 2386
2025
Q1 		$495K Sell
40,255
-597
-1% -$8.42K ﹤0.01% 1607
2024
Q4 		$540K Sell
40,852
-3,084
-7% -$52.8K ﹤0.01% 1648
2024
Q3 		$846K Sell
43,936
-271
-0.6% -$5.6K ﹤0.01% 1442
2024
Q2 		$908K Buy
+44,207
New +$925K 0.01% 1372

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Corebridge Financial's SNDX Position: Q2 2025 in Review

Corebridge Financial sold out of Syndax Pharmaceuticals (SNDX) in Q2 2025, closing a stake of 40,255 shares — an estimated $495K sold.

Corebridge Financial first reported a position in SNDX in Q2 2024 and held it in 4 quarters. The position peaked at $908K in Q2 2024. 216 funds tracked by Wall St. Rank hold SNDX as of Q2 2025.

  • Corebridge Financial reported no remaining Syndax Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 40,255 Syndax Pharmaceuticals shares in Q2 2025, an estimated $495K.
  • Corebridge Financial first reported a position in Syndax Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Syndax Pharmaceuticals position peaked at $908K in Q2 2024.
  • 216 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.